Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 2

Anlotinib and benmelstobart before kidney-sparing surgery for localized kidney cancer

Tests anlotinib with benmelstobart before partial nephrectomy in adults with localized renal cell carcinoma.

Plain-language title generated from the registry record
Registry title: Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy

Key facts

Where
Beijing, Changchun, Changsha, Hangzhou, Kunming, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, and Zhengzhou, ChinaSee the 14 sites
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed, localized kidney cancer (renal cell carcinoma) who are planned for partial nephrectomy (surgery to remove part of the kidney).

Age
18 to 75 years
Sex
Men and women can join.
Disease stage
Newly diagnosed cT1bN0M0 renal cell carcinoma, with at least one measurable lesion (RECIST version 1.1).
Earlier treatment
No earlier systemic treatment for renal cell carcinoma, such as targeted therapy, immunotherapy, investigational therapy or hormone therapy.

Main reasons for not taking part

  • A solitary kidney tumor
  • Tumors in both kidneys, or 2 or more tumors in one kidney
  • Hereditary or familial kidney tumors (for example von Hippel-Lindau disease)
  • A past kidney transplant

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT07627464, who can take part

Where in China

  • Peking University Third HospitalBeijing, ChinaContact: Shudong ZhangNo longer taking part
  • Jilin Provincial Cancer HospitalChangchun, ChinaContact: Changdong ZhouNo longer taking part
  • Hunan Provincial Cancer HospitalChangsha, ChinaContact: Xie YuNo longer taking part
  • The First Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaContact: Dan XiaNo longer taking part
  • Yunnan Provincial Cancer HospitalKunming, ChinaContact: Yong YangNo longer taking part
  • Nanjing Drum Tower hospitalNanjing, ChinaContact: Hongqian GuoNo longer taking part
  • The First Affiliated Hospital of Guangxi Medical UniversityNanning, ChinaContact: Jiwen ChenNo longer taking part
  • The Affiliated Hospital of Qingdao UniversityQingdao, ChinaContact: Ke WangNo longer taking part
  • Huadong Hospital Affiliated to Fudan UniversityShanghai, ChinaContact: Hailiang ZhangNo longer taking part
  • Liaoning Provincial Cancer HospitalShenyang, ChinaContact: Bing HuNo longer taking part
  • Shanxi Province Cancer HospitalTaiyuan, ChinaContact: Xuebing HanNo longer taking part
  • Tianjin Medical University Cancer Institute and HospitalTianjin, ChinaContact: Yao Xin, Ph.D.No longer taking part
  • Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaContact: Xiaoping ZhangNo longer taking part
  • The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaContact: Xuepei ZhangNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Tianjin Medical University Cancer Institute and Hospital
Trial code
NCT07627464
Record updated
4 June 2026
Original description
Evaluation of long-term renal function improvement, surgical safety, as well as efficacy and safety of preoperative anlotinib hydrochloride capsules combined with benmelstobart injection versus surgery in patients with localized renal cell carcinoma undergoing partial nephrectomyRead full original descriptionShow less

A Multicenter, Randomized Controlled Phase II Study of Neoadjuvant Anlotinib Hydrochloride Capsules Combined With Benmelstobart Injection Versus Surgery Alone for Localized Renal Cell Carcinoma Planned for Partial Nephrectomy

Evaluation of long-term renal function improvement, surgical safety, as well as efficacy and safety of preoperative anlotinib hydrochloride capsules combined with benmelstobart injection versus surgery in patients with localized renal cell carcinoma undergoing partial nephrectomy

Inclusion: Aged between 18 and 75 years, inclusive; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Subjects with newly diagnosed cT1bN0M0 renal cell carcinoma (RCC) scheduled to undergo partial nephrectomy; Have at least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; No prior systemic therapy for renal cell carcinoma, including but not limited to targeted therapy, immunotherapy, investigational therapy, or hormone therapy.

Exclusion: Subjects with a prior history of renal transplantation; Subjects with hereditary or familial renal tumors (e.g., von Hippel-Lindau [VHL] disease); Subjects with a solitary kidney tumor; Subjects with bilateral renal tumors or unilateral multiple renal tumors (n ≥ 2).

ClinicalTrials.gov NCT07627464